- Home
- RDI vs ANVS Comparison
RDI vs ANVS Comparison
Compare RDI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | ANVS |
|---|---|---|
| Founded | 1937 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 50.4M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RDI | ANVS |
|---|---|---|
| Price | $1.86 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 43.5K | ★ 930.6K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | N/A |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $1.04 |
| 52 Week High | $2.41 | $5.50 |
Technical Indicators
Market Signals| Indicator | RDI | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 43.07 |
| Support Level | $0.99 | $1.04 |
| Resistance Level | $2.13 | $1.43 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 20.30 | 28.81 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.